Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085969 · ClinicalTrials.gov registry record · Phase 2
Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT00085969 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 99 participants.
The verdict
NCT00085969, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of a 28-day regimen of exenatide (AC2993), given as a monotherapy to subjects with type 2 diabetes mellitus.
Interventions
- DRUG Placebo 0.04 mL twice daily
- DRUG Placebo 0.04 mL once daily
- DRUG Placebo 0.08 mL once daily
- DRUG B - Exenatide 10 mcg twice daily
- DRUG C - Exenatide 10 mcg once daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2003-09 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085969
The ClinicalTrials.gov registry entry for NCT00085969 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo 0.04 mL twice daily is the first listed.
NCT00085969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00085969 about?
NCT00085969 is a clinical study titled "Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the safety and efficacy of a 28-day regimen of exenatide (AC2993), given as a monotherapy to subjects with type 2 diabetes mellitus.
What is the current status of trial NCT00085969?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2003-09. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00085969?
The interventions under investigation include: Placebo 0.04 mL twice daily (DRUG), Placebo 0.04 mL once daily (DRUG), Placebo 0.08 mL once daily (DRUG), B - Exenatide 10 mcg twice daily (DRUG), C - Exenatide 10 mcg once daily (DRUG).
Who is sponsoring clinical trial NCT00085969?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.